Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease
Open Access
- 23 August 2024
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Abstract
No abstract availableKeywords
Funding Information
- National Key R&D Program of China
This publication has 15 references indexed in Scilit:
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsNew England Journal of Medicine, 2024
- Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2024
- The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B‐cell acute lymphoblastic leukemia patients detected by next‐generation sequencingCancer Medicine, 2023
- Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic LeukemiaTransplantation and Cellular Therapy, 2023
- Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual diseaseBritish Journal of Haematology, 2023
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic LeukemiaJAMA Oncology, 2017
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017
- Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemiaBlood, 2010
- Status of minimal residual disease testing in childhood haematological malignanciesBritish Journal of Haematology, 2008
- Rituximab for steroid-refractory chronic graft-versus-host diseaseBlood, 2006